303 related articles for article (PubMed ID: 34289585)
1. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.
Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Shin KS; Jo DY
Intern Med; 2022 Dec; 61(23):3483-3490. PubMed ID: 35527026
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms].
Hu BD; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):813-818. PubMed ID: 35680810
[TBL] [Abstract][Full Text] [Related]
6. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
7. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
8. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
[TBL] [Abstract][Full Text] [Related]
9. Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
Blood Res; 2022 Mar; 57(1):59-68. PubMed ID: 35256550
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
11. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
Beleva EA
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
[TBL] [Abstract][Full Text] [Related]
12. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
15. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
17. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.
Al-Mashdali AF; Aldapt MB; Rahhal A; Hailan YM; Elhakeem I; Ali EA; Rozi W; Yassin MA
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766480
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
20. Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample.
Ulanja MB; Beutler BD; Antwi-Amoabeng D; Apanga PA; Moody AE; Willyard CE; Gullapalli N; Boampong-Konam K; Bowman AT
Thromb Res; 2020 Oct; 194():72-81. PubMed ID: 32788124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
